What is Rational Combined Antihypertensive Therapy: ACE Inhibitor + Diuretic or Calcium Channel Blocker?

A.D. Radchenko

Abstract


This article is a literature review of data about advantages of start combination antihypertensive therapy. There was explained the definition of rational combination. There were dwelt the items whether the combination of angiotensin converting enzyme inhibitors and diuretic or calcium antagonist are still rational and which diuretics or calcium antagonists are better in combination with angiotensin converting enzyme inhibitors for long antihypertensive therapy.


Keywords


arterial hypertension; combined therapy; angiotensin converting enzyme inhibitors; diuretics

References


Беленков Ю.Н., Мареев В.Ю., от имени рабочей группы исследования ЭПИГРАФ. Эналаприл плюс индапамид в лечении стабильной артериальной гипертонии: оценка эффективности и безопасности Рациональной комбинированной Фармакотерапии (Эпиграф). Первые результаты Российского многоцентрового исследования // Сердце. — 2005. — Т. 2, № 4. — С. 3-10.

Беленков Ю.Н. и рабочая группа исследования ЭПИГРАФ-2. Эналаприл Плюс Индапамид в лечении АГ: оценка эффективности и безопасности рациональной фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2 // Сердце. — 2005. — Т. 4, № 5. — С. 277-286.

Горбась І.М. Програма профілактики і лікування артеріальної гіпертензії в Україні: підсумки виконання // Здоров’я України. Тематичний номер. — 2011. — № 3. — С. 32-34

Корзун А.И., Кириллова М.В. Сравнительная характеристика ингибиторов АПФ. — СПб.: ВМедА, 2003. — 24 с.

Настанова та клінічний протокол надання медичної допомоги «Артеріальна гіпертензія». Наказ МОЗ України № 384 від 24.05.2012. — К., 2012. — 107 с.

Радченко Г.Д., Сіренко Ю.М. Досвід застосування лізиноприлу (Вітоприл) у пацієнтів з м’якою та помірною артеріальною гіпертензією // Укр. мед. часопис. — № 2. — С. 31-36.

Радченко А.Д. Что такое рациональная комбинированная антигипертензивная терапия и остается ли таковой комбинация ингибитора АПФ и дуретика // Артериальная гипертензия. — 2014. — № 2. — С. 97-111.

Савенков М.П., Иванов С.Н., Иванова С.В., Соломонова Л.А. и др. Варианты применения фиксированной комбинации лизиноприла и амлодипина при лечении артериальной гипертонии // РМЖ. — 2010. — Т. 18, № 3. — С. 106-108.

Сіренко Ю.М., Радченко Г.Д., Поліщук С.А. від імені учасників багатоцентрового дослідження Еналаприл плюс індапамід при лікуванні артеріальної гіпертензії: оцінка ефективності та безпеки раціональної фармакотерапії застосування нефіксованої комбінації еналаприлу і індапаміду (ЕНЗИКС) (результати багатоцентрового дослідження ЕПІГРАФ-2 в Україні) // Укр. мед. часопис. — 2007. — № 3. — С. 61-70.

Aronow W., Flag J., Pepine C., Barkis G. et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly // JACC. — 2011. — Vol. 57. — P. 2037-2114.

2007 European Society of Hypertension — European Society of Cardiology guidelines for management of arterial hypertension // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management ofarterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Amery A., Berthaux P., Bulpitt C. et al. Glucose intolerance during diuretic therapy: results of trial by the European Working Party on Hypertension in the Elderly // Lancet. — 1978. — Vol. 1. — P. 681-683.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. — 2002. — Vol. 288. — P. 2981-2997.

Ball S., Hall A., Murray G. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing // J. Am. Coll. Cardiol. — 1995. — Vol. 25. — S42-S46.

Banegas J., Esther López-García E., Dallongeville J. et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study // European Heart Journal. — 2011. — Vol. 32. — P. 2143-2152.

Barzilay J.I., Davis B.R., Cutler J.A. et al. Fasting glucose levels and incident di abetesmellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch Intern Med. — 2006. — Vol. 166. — P. 2191-2201.

Bjorklund K., Lind L., Zethelius B., Berglund L., Lithell H. Prognostic significance of 24-h ambulatory blood pressure characte-ristics for cardiovascular morbidity in a population of elderly men //

J. Hypertens. — 2004. — Vol. 22. — P. 1691-1697.

Byrd J.B., Zeng C., Tavel H.M. et al. Combination therapy as initial treatment for newly diagnosed hypertension // Am. Heart J. — 2011. — Vol. 162(2). — P. 340-346.

Csaba F., Gyorgy A., Peter K. et al. AmlodipinLisinopril Fix-combination in patients with essential hypertension (ALFESS study) // Hypertension and Neurology. — 2009. — Vol. 13, № 2. — P. 81-88.

Chockalingham A., Fodor J.G. Treatment of raised blood pressure in the population. The Canadian experience //Am. J. Hypertens. — 1998. — Vol. 11. — P. 747-749.

Colhoun H.M., Dong W., Poulter N.R. Blood pressure scree-ning, management and control in England: results from the health survey for England 1994 // J. Hypertens. — 1998. — Vol. 16. — P. 747-752.

Corrao G., Nicotra F., Parodi A. et al. Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice // Hypertension. — 2011. — Vol. 58. — P. 566-572.

Dahloеf B., Devereux R.B., Kjeldsen S.E., Julius S., Be-evers G., de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Daly C., Fox K., Remme W. еt al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy // Eur. Heart J. — 2005. — Vol. 26. — P. 1369-1378

Dorsh M., Gillespie B., Erikson S. et al. Chlorthalidone reduces cardiovascular events compared with Hydrochlorthiazide: a retrospective cohort analysis // Hypertension. — 2011. — Vol. 57. — P. 689-694.

Ernst M.E., Carter B.L., Goerdt C.J. et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure // Hypertension. — 2006. — Vol. 47. — Р. 352-358.

Farsang C. A HAMLET Vizsgalok neveben // Hypertonia es nephrologia. — 2004. — Vol. 8(2). — P. 72-78.

Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362. — P. 782-788.

Guidelines on the management of stable angina pectoris. The Task Force on the management of stable angina pectoris of the European Society of Cardiology // Eur. Heart J. — 2013. — Doi: 10.1093/eurheartj/eht296.

Girerd X. et al. Analysis of the use of antihypertensive drugs in five European countries in 2010. — ESH London, 29th April.

Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patiens treated with inda-pamide SR 1,5 mg versus enalapril 20 mg: the LIVE study // J. Hypertens. — 2000. — Vol. 18(10). — P. 1465-1475.

Gradman A.H., Parisé H., Lefebvre P. et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study // Hypertension. — 2013. — Vol. 61(2). — P. 309-318.

Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study // N. Engl. J. Med. — 2000. — Vol. 342. — P. 905-912.

Hirata K., Vlachopoulos C., Adji A., O’Rourke M.F. Benefits from angiotensin-converting enzyme inhibitor «beyond blood pressure lowering»: beyond blood pressure or beyond the brachial artery? [published correction appears in J. Hypertens. 2005; 23: 903-904] //

J. Hypertens. — 2005. — Vol. 23. — P. 551-556.

http://www.theheart.org/article/1443111.do

Huang K., Dai G. The effect and mechanism of forsinopril on ventricular hypertrophy of SHR and left ventricular pressure overloading rat // J. Huazriong Univ Sci Technolog Med Sci. — 2002. — Vol. 22. — P. 17-20.

Jamerson K., Weber M.A., Bakris G.L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients // N. Engl. J. Med. — 2008. — Vol. 359. — P. 2417-2428.

Jeunemaitre X., Charru A., Chatellier G. et al. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension // Am. J. Cardiol. — 1988. — Vol. 62. — P. 1072-1077.

Kikuya M., Hozava A., Ohokubo T. et al. Prognostic Significance of Blood Pressure and Heart Rate Variabilities // Hypertension. — 2000. — Vol. 36. — P. 901-906.

Krause T., Lovibond K., Caulfield M. et al. Management of hypertension: summary of NICE guildance // BMJ. — 2011. — Vol. 343. — P. 48-91.

Kronish I., Woodward M., Sergie Z. et al. Meta-Analysis Impact of Drug Class on Adherence to Antihypertensives // Circulation. — 2011. — Vol. 123. — P. 1611-1621.

Langford H.G., Cutter G., Oberman A., Kansal P., Russell G. The effect of thiazide therapy on glucose, insulin and cholesterol metabolism and of glucose on potassium: results of a cross-sectional study in patients from the Hypertension Detection and Follow-up Program // J. Hum. Hypertens. — 1990. — Vol. 4. — P. 491-500.

Leonetti G., Rappelli A., Salvetti A., Scapellato L. Long-term effects of indapamide: final re-sults of a two-year Italianmulticenter study in systemic hypertension // Am. J. Cardiol. — 1990. — Vol. 65. — P. 67H-71H.

Madkour H., Gadallah M., Riveline B. et al. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension // Am. J. Car­diol. — 1996. — Vol. 77. — P. 23-25B.

Mancia G., Seravalle G., Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists // Am. J. Hypertens. — 2003. — Vol. 16. — P. 1066-1073.

Marre M., Garcia Puig J., Kokot F. et al. Effect of indapamide SR on microalbuminuria — the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) — rationale and protocol for the main trial // J. Hypertens. Suppl. — 2003. — Vol. 21(1). — P. 19-24S.

Marre M., Garcia-Puig J., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction hypertensive patients with type 2 diabetic: the NESTOR study // J. Hypertens. — 2004. — Vol. 22. — P. 1613-1622.

Messerli F., Bangalore S. Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies // Am. J. Med. — 2011. — Vol. 124. — P. 896-899.

Mourad J.J., Waeber B., Zannad F. et al. Investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach // J. Hypertens. — 2004. — № 22. — Р. 2379-2386.

Multiple Risk Factor Intervention Trial Research Group. Mortality After 101/2 Years for Hypertensive Participants in the Multiple Risk Factor Intervention Trial // Circulation. — 1990. — Vol. 82. — P. 1616-1628.

Nissen S., Tuzcu E., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trail // JAMA. — 2004. — Vol. 292. — P. 2217-2225.

Ogihara Т., Saruta Т., Rakugi H.et al. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial // Hypertension Research. — 2015. — Vol. 38. — P. 89-96.

Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group // N. Engl. J. — 1996. — Vol. 335. — P. 1107-1114.

Plavinik F.L., Rodrigues C.I., Zanella M.T., Ribeiro A.B. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy // Hypertension. — 1992. — Vol. 19 (suppl.). — P. II26-II29.

Poulter N., Wedel H., Dahlof B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trail-Blood Pressure Lowering Arm // Lancet. — 2005. — Vol. 366. — P. 907-913.

PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or trancient ischaemic attack // Lancet. — 2001. — Vol. 358. — P. 1033-1041.

Rothwell P. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension // The Lancet. — 2010. — Vol. 375. — P. 938-948.

Saruta Т., Ogihara Т., Saito I. et al. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability // Hypertens. Res. — 2015. — Vol. 38(2). — P. 132-136.

Schrier R., Estacio R., Mehler Р., Hiatt W. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial // Nature Clinical Practice Nephrology. — 2007. — Vol. 3. — P. 428-438.

Shafi T., Appel L.J., Miller E.R. 3rd, Klag M.J., Parekh R.S. Changes in serum potassium mediate thiazide-induced diabetes // Hypertension. — 2008. — Vol. 52. — P. 1022-1029.

Sharabi Y., Adler E., Shamis A., Nussinovitch N., Marko-vitz A., Grossman E. Efficacy of addon aldosterone receptor blocker in uncontrolled hypertension // Am. J. Hypertens. — 2006. — Vol. 19. — P. 750-755.

Siscovick D., Raghunathan T., Psaty B. et al. Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest // N. Engl. J. Med. — 1994. — Vol. 330. — P. 1852-1857.

Stears A.J., Woods S.H., Watts M.M. et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension // Hypertens. — 2012. — Vol. 59. — P. 934-942.

Teo K.K., Burton J., Buller C. et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) // Circulation. — 2000. — Vol. 102. — P. 1748.

The CAFÉ Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trail (ASCOT) Investigators, CAFÉ Steering Committee and Writing Committee. Differential Impact of Blood Pressure-Lowering Drugs on Cantral aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFÉ) Study // Circulation. — 2006. — Vol. 113. — P. 1213-1225.

The Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease // European Heart Journal. — 2004. — Vol. 25. — P. 1454-1470.

The Task force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guildelines on the management of stable angina pectoris // European Heart Journal. — Doi: 10.1093/eurheartj/ehj001.

Verdecchia P., Reboldi G., Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects // Hypertension. — 2004. — Vol. 43. — P. 963-969.

Vermes E., Ducharme A., Bourassa M.G. et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the studies of left ventricular dysfunction (SOLVD) // Circulation. — 2003. — Vol. 107. — P. 1291-1296.

Wald D., Law M., Morris J. et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials // Am. J. Med. — 2009. — Vol. 122. — P. 290-300.

Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical values in the VALUE trial // Lancet. — 2004. — Vol. 363. — P. 2047-2049.

Weber M.A., Jamerson K., Bakris G.L. et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomized controlled trial // Lancet. — 2012. — Doi: 10.1016/S0140-6736(12)61343-9.

Wing L.M., Reid C.M., Ryan P. et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly // N. Engl. J. Med. — 2003. — Vol. 348. — P. 583-592.




DOI: https://doi.org/10.22141/2224-1485.3.41.2015.80647

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru